Corrections:

Xiao Wang^1,2, Shasha Liu^1,3, Ling Cao^1,2, Tengfei Zhang¹, Dongli Yue^1,2, Liping Wang², Yu Ping^1,3, Qianyi He², Chaoqi Zhang^1,2, Meng Wang¹, Xinfeng Chen^1,2, Qun Gao^1,2, Dan Wang^1,2, Zhen Zhang¹, Fei Wang¹, Li Yang¹, Jieyao Li^1,2, Lan Huang¹, Bin Zhang⁴ and Yi Zhang^1,2,3,5

¹Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
²Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
³School of Life Sciences, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
⁴Department of Hematology/Oncology, School of Medicine, Northwestern University, Chicago, IL 60611, USA
⁵Key Laboratory for Tumor Immunology and Biotherapy of Henan Province, Zhengzhou, Henan 450052, P.R. China

Published: May 19, 2023

Copyright: © 2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 2D, parts of the NC and miR-29a-3p panels are accidental duplicates. The corrected Figure 2, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:86592–86603. DOI: https://doi.org/10.18632/oncotarget.21246

Figure 2: Overexpression of miR-29a-3p inhibited cancer cell growth and migration in vitro and in vivo. (A) QRT-PCR analysis of miR-29a-3p expression in normal human hepatic cell line (LO2) and HCC cells lines (SMMC-7721, Hep3B, HepG2, and Huh 7). (B) Proliferation ability test by CCK8 assay of HepG2 cells after transfection with miR-29a-3p mimics, negative control (NC) or no transfection (untreated). (C) Colony formation assay and statistical results in HepG2 cells after transfection with miR-29a-3p mimics, NC or untreated. (D) Wound healing assay of HepG2 cells after transfection with the miR-29a-3p mimics, NC or untreated. (E) Transwell migration assay of HepG2 cells after transfection with the miR-29a-3p mimics, NC or untreated. (F) Functional test of miR-29a-3p in vivo and statistical results. (*P < 0.05, **P < 0.01, ***P < 0.001).